Advanced Diagnostics for Pharmacists
Take an integrated approach to point-of-care testing
BD Diagnostic Solutions is Now Waters Advanced Diagnostics
BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life science and diagnostics leader driven by innovation and a relentless commitment to our customers.
As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.
Advanced Diagnostics for Pharmacists
Empower pharmacists with our diagnostic solutions portfolio, including point-of-care testing capabilities. Portable, convenient analyzers offer rapid results to guide your patients to the appropriate path to care.
BD Veritor™ Plus System
Integrated, digitally connected testing that removes any guesswork—by interpreting and providing rapid, clear results for SARS-CoV-2, Flu A+B, SARS-CoV-2 & Flu A+B,* Group A Strep, and RSV—so you can move forward with confidence.
Discover how easy sample collection can simplify testing workflows for reliable results you can act on.
Get in touch with a sales representative
Diagnostic tests classify infections and guide therapies, enabling clinicians to implement effective antimicrobial interventions
-
Advanced Diagnostics aims to optimize patient care pathways through essential tests crucial for making treatment decisions.
-
Advanced Diagnostics are designed to support your ability to minimize the effort to get accurate diagnostic results and help keep your lab ahead of the curve.
-
Advanced Diagnostics optimizes patient care pathways through essential tests crucial for treatment decisions.
References
References:
- Ngo A, Gandhi P, Miller WG. Frequency that laboratory tests influence medical decisions. J ApplLab Med. 2017;1(4):410-414.
- Hawkins R. Managing the pre- and post-analytical phases of the total testing process. Ann Lab Med. 2012;32:5-16.
Notes:
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Disclaimer:
This business has been acquired by Waters Corporation (“Waters”). For products referenced on this page, the legal manufacturer remains Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under the regulatory authority of BD. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary waters.com/bdtransaction.
